Written by Jim Albert Eldersburg, Maryland A cancer drug has been shown to potentially rescue some of the damaging effects of DUX4, the gene implicated in FSH muscular dystrophy…. Read More »
Intriguing research on tyrosine kinase inhibition as a potential therapy for FSHD: Sunitinib rescues muscle cells’ ability to develop
Our Manhattan Project
The FSH Society’s March 11, 2017, meeting in Manhattan was a milestone in our efforts to nurture a network of stakeholders in one of our most concentrated urban centers. Hosted… Read More »
Double Your Donation… Easily and Free!
Corporate Matching Gifts: Does Your Company Match Your Donation? Did you know many companies offer a matching gift program to encourage philanthropy among their employees? And that some companies will even… Read More »
FSH Society Awards $541,133 in Funding for FSH Muscular Dystrophy Research
Boston-based Non-profit Awards New Grants to Facilitate Search for a Cure BOSTON – April 5, 2017 – Today the FSH Society, a world leader in combating facioscapulohumeral muscular dystrophy (FSHD),… Read More »
Update on Clinical Trial A083-02: a Phase 2 Clinical Study of ACE-083 in FSHD
The FSH Society has a long history of partnering with biotech and pharmaceutical companies to facilitate recruitment of patients and families for focus groups, provide patient input to clinical outcome… Read More »